Simulations Plus (NASDAQ:SLP) Releases FY 2024 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.540-0.560 for the period, compared to the consensus estimate of 0.550. The company issued revenue guidance of $69.0 million-$72.0 million, compared to the consensus revenue estimate of $70.9 million. Simulations Plus also updated its FY24 guidance to $0.54-0.56 EPS.

Simulations Plus Trading Up 1.5 %

NASDAQ:SLP opened at $46.86 on Wednesday. The firm has a market cap of $936.73 million, a P/E ratio of 88.42 and a beta of 0.72. The stock’s 50 day simple moving average is $47.81 and its 200-day simple moving average is $44.18. Simulations Plus has a 12-month low of $32.69 and a 12-month high of $52.69.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings data on Wednesday, April 3rd. The technology company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. Simulations Plus had a return on equity of 7.95% and a net margin of 16.22%. The firm had revenue of $18.31 million for the quarter, compared to analyst estimates of $17.31 million. During the same quarter in the prior year, the company posted $0.20 earnings per share. Simulations Plus’s quarterly revenue was up 16.2% on a year-over-year basis. Research analysts forecast that Simulations Plus will post 0.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SLP has been the topic of a number of recent analyst reports. Oppenheimer upped their price objective on Simulations Plus from $55.00 to $65.00 and gave the stock an outperform rating in a report on Thursday, June 13th. Craig Hallum upped their price objective on Simulations Plus from $51.00 to $56.00 and gave the stock a buy rating in a report on Thursday, June 13th. Finally, William Blair started coverage on Simulations Plus in a report on Friday, June 28th. They issued an outperform rating on the stock.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $45.95, for a total value of $919,000.00. Following the completion of the transaction, the director now owns 3,580,857 shares in the company, valued at $164,540,379.15. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Daniel L. Weiner sold 3,250 shares of Simulations Plus stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $48.31, for a total transaction of $157,007.50. Following the completion of the sale, the director now owns 8,759 shares in the company, valued at approximately $423,147.29. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $45.95, for a total value of $919,000.00. Following the sale, the director now owns 3,580,857 shares of the company’s stock, valued at approximately $164,540,379.15. The disclosure for this sale can be found here. Insiders sold a total of 44,500 shares of company stock worth $2,072,198 over the last 90 days. 20.90% of the stock is currently owned by corporate insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.